- Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
- Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
- Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
- Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
- Can-Fite Granted Key NASH Patent in Israel
- Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Can Fite Biopharma Ltd (CANF:ASQ) closed at 0.844, 8.21% above its 52-week low of 0.78, set on Jun 15, 2022.
0.78Jun 15 20222.60Dec 20 2021
Data delayed at least 15 minutes, as of Jul 06 2022 21:10 BST.